Minimally Invasive Coronary Artery Bypass Supported by Cangrelor
Recruiting now
Conditions studied: Coronary Artery Disease, Antiplatelet Therapy, Minimally Invasive Coronary Revascularization Surgery
In brief
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip. The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand. Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications? Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure. This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
Key facts
- Study ID
- NCT07514962
- Run by
- Cardiocentro Ticino
- People needed
- 30
- Starts
- 2024-05-12
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Istituto Cardiocentro Ticino — Lugano, Ch/ti, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.